Latest Earnings Results: Q3 '26
Estimated EPS
-$0.40
Reported EPS
-$0.15
Surprise
+62.41%
Estimated Rev
$12.22M
Reported Rev
---
Surprise
---
• Reported GAAP EPS of -$0.15 up 82.35% YoY • Reported revenue of $34.06M up 190.37% YoY • Bicycle Therapeutics reported cash and cash equivalents of $469.9M as of September 30, 2026, with expected cash runway into 2030, as stated in quarterly results.
Bullish Takeaway
Bicycle Therapeutics received FDA Orphan Drug Designation for nuzefatide in pancreatic cancer, is actively enrolling a Phase 2 trial, and expects first company-sponsored BT1702 radioligand trial initiation in 2H 2027.
Bearish Takeaway
Bicycle Therapeutics reported cash and cash equivalents of $469.9M versus $628.1M, deprioritized zelenectide pevedotin for internal development, and disclosed the risk that clinical trials may have unsatisfactory outcomes as of September 30, 2026.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.44 | -- | -- | N/A |
Q3 '26 | -$0.40 | -$0.15 | 62.41% | BEAT |
Q2 '26 | -$0.66 | -$0.72 | -8.42% | MISSED |
Q1 '26 | -$0.62 | -$0.87 | -40.12% | MISSED |
Q4 '25 | -$0.94 | -$0.29 | 69.06% | BEAT |